The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy of pacritinib in patients with myelofibrosis who have both thrombocytopenia and anemia.
 
Pankit Vachhani
Consulting or Advisory Role - Abbvie; Amgen; Blueprint Medicines; Cogent Biosciences; CTI BioPharma Corp; Genentech/Roche; GlaxoSmithKline; Incyte; Karyopharm Therapeutics; Merck; MorphoSys; Novartis; Pfizer; Stemline Therapeutics
Speakers' Bureau - Blueprint Medicines; Incyte
Research Funding - Abbvie (Inst); Amgen (Inst); Astex Pharmaceuticals (Inst); Blueprint Medicines (Inst); Constellation Pharmaceuticals (Inst); CTI BioPharma Corp (Inst); Gilead/Forty Seven (Inst); Incyte (Inst); Kartos Therapeutics (Inst); Seagen (Inst); Takeda (Inst)
 
Vikas Gupta
Stock and Other Ownership Interests - Syndax
Honoraria - Abbvie; Bristol-Myers Squibb/Celgene; CTI biophara; GlaxoSmithKline; Incyte; Novartis; Pfizer
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb/Celgene; CTI BioPharma Corp; GlaxoSmithKline; Incyte; Novartis
Research Funding - Abbvie (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Patent on MPN24 a gene signature to predict outcome of Myelofibrosis (Inst)
 
Francesca Palandri
Honoraria - Abbvie; Amgen; AOP Orphan Pharmaceuticals; Celgene; Celgene/Bristol-Myers Squibb; CTI; GlaxoSmithKline; Grifols; Karyopharm Therapeutics; MorphoSys; Novartis; Sierra Oncology; SOBI
Consulting or Advisory Role - Abbvie; Amgen; AOP Orphan Pharmaceuticals; Celgene; Celgene/Bristol-Myers Squibb; CTI; GlaxoSmithKline; Grifols; Karyopharm Therapeutics; MorphoSys; Novartis; Sierra Oncology; SOBI
 
Purvi Suthar
Employment - CTI BioPharma Corp; SOBI
Stock and Other Ownership Interests - CTI BioPharma Corp
 
Sarah Buckley
Employment - CTI BioPharma Corp; SOBI
Stock and Other Ownership Interests - CTI BioPharma Corp
 
Karisse Roman-Torres
Stock and Other Ownership Interests - CTI BioPharma Corp
Consulting or Advisory Role - CTI BioPharma Corp; SOBI
 
Prithviraj Bose
Honoraria - Abbvie; Blueprint Medicines; BMS; Cogent Biosciences; CTI BioPharma Corp; GlaxoSmithKline; Incyte; Ionis Pharmaceuticals; Jubilant Therapeutics; Karyopharm Therapeutics; Morphic Therapeutic; MorphoSys; Novartis; Pharmaessentia
Consulting or Advisory Role - Ono Pharmaceutical; Sierra Oncology
Research Funding - Blueprint Medicines (Inst); Bristol Myers Squibb (Inst); Celgene (Inst); Celgene (Inst); Cogent Biosciences (Inst); Constellation Pharmaceuticals (Inst); CTI BioPharma Corp (Inst); Geron (Inst); Incyte (Inst); Ionis Pharmaceuticals (Inst); Janssen (Inst); Kartos Therapeutics (Inst); Karyopharm Therapeutics (Inst); MorphoSys (Inst); Telios (Inst)